Welcome to our dedicated page for Trevi Therapeutics news (Ticker: TRVI), a resource for investors and traders seeking the latest updates and insights on Trevi Therapeutics stock.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) is a clinical-stage biopharmaceutical company developing Haduvio™ (oral nalbuphine extended-release) as an investigational therapy for chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). The Trevi Therapeutics news feed on this page brings together company announcements, clinical data updates, and financial disclosures that relate directly to TRVI stock and its development programs.
News items commonly include results from key clinical trials such as the Phase 2b CORAL trial in IPF chronic cough and the Phase 2a RIVER trial in RCC, along with information on additional studies like respiratory safety and drug–drug interaction trials. Trevi’s releases also describe regulatory milestones, including End-of-Phase 2 interactions with the U.S. Food and Drug Administration for chronic cough in IPF, and outline planned Phase 3 and Phase 2b programs.
Investors and followers of TRVI can also find corporate and financial updates in the news stream, including quarterly financial results, capital-raising transactions, and participation in healthcare and investor conferences. Management changes and other material events are typically reported through press releases that are also furnished to the U.S. Securities and Exchange Commission on Form 8-K.
By reviewing the Trevi Therapeutics news page, readers can monitor how the company reports progress in its chronic cough indications, how clinical data are presented at scientific meetings, and how management describes its strategy for advancing Haduvio. This centralized news view helps provide context for developments that may influence perceptions of Trevi’s clinical pipeline and regulatory trajectory.
Trevi Therapeutics (Nasdaq: TRVI) reported third-quarter 2025 results and clinical updates on November 13, 2025. The company ended Q3 2025 with $194.9 million in cash, cash equivalents and marketable securities and expects a cash runway into 2028. Trevi plans to request an End-of-Phase 2 meeting with the FDA in Q4 2025 and to initiate a Phase 3 IPF chronic cough program in H1 2026. A Phase 1 IPF safety study (TIDAL) sentinel cohort showed no safety signals; enrollment completion and study data are expected in Q4 2025. A Phase 1 drug-drug interaction study showed no clinically meaningful PK interactions with pirfenidone or nintedanib. Topline Phase 2b CORAL and Phase 2a RIVER results were presented at CHEST 2025 and ERS Congress 2025. Q3 2025 net loss was $11.8 million.
Trevi Therapeutics (Nasdaq: TRVI) announced a conference call and live audio webcast for Thursday, November 13, 2025 at 4:30 p.m. ET to provide a corporate update and review third quarter financial results for the period ended September 30, 2025.
Senior management will host the call; domestic dial-in is (877) 870 4263 and international dial-in is (412) 317 0790. No access code is required. A live audio webcast will be available from the Investors & News section at www.TreviTherapeutics.com, with an archived replay accessible on the company website for 30 days after the event.
Trevi Therapeutics (Nasdaq: TRVI) announced management will participate in the Stifel 2025 Healthcare Conference in New York on November 11–12, 2025.
A fireside chat featuring Jennifer Good, President and CEO, and James Cassella, Ph.D., Chief Development Officer, is scheduled for Tuesday, November 11, 2025 at 3:20 p.m. ET. Company executives will also hold investor meetings with conference attendees. The fireside chat and meetings will be available for in-person attendees.
Trevi Therapeutics (Nasdaq: TRVI) announced two accepted abstracts for presentation at the CHEST 2025 Annual Meeting in Chicago, Oct 19–22, 2025. Key efficacy and safety results from the Phase 2b CORAL dose‑ranging trial of oral nalbuphine ER in patients with idiopathic pulmonary fibrosis (IPF) will be presented orally by Philip Molyneaux on Oct 21, 1:45–2:30pm CDT. Patient‑reported outcomes from the Phase 2a RIVER proof‑of‑concept trial in refractory chronic cough (RCC) will be presented as a poster by Imran Satia on Oct 21, 1:45–2:30pm CDT. Both items appear in late‑breaking scientific abstract sessions and target clinicians and researchers focused on chronic cough and interstitial lung disease.
Trevi Therapeutics (Nasdaq: TRVI) announced that data from its Phase 2a RIVER trial of Haduvio™ (oral nalbuphine ER) will be presented in two poster sessions at the European Respiratory Society (ERS) Congress 2025 in Amsterdam. The presentations will focus on the efficacy, safety, and responder analysis of nalbuphine ER in treating refractory chronic cough (RCC).
The posters will be presented on September 28-29, 2025, covering results from the trial investigating Haduvio™ for chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease, and RCC.
Trevi Therapeutics (NASDAQ:TRVI), a clinical-stage biopharmaceutical company, has announced its participation in six major healthcare and industry conferences throughout September 2025. The company, which is developing Haduvio™ (oral nalbuphine ER) for chronic cough conditions, will be represented by senior management at various events including the Wells Fargo Healthcare Conference, Cantor Global Healthcare Conference, Morgan Stanley Global Healthcare Conference, H.C. Wainwright Global Investment Conference, Leerink Partners Biopharma Summit, and the European Respiratory Society Congress.
A notable highlight includes a fireside chat scheduled for September 9 at 4:05 p.m. ET during the Morgan Stanley conference, which will be available via live presentation.
Trevi Therapeutics (NASDAQ: TRVI) reported significant achievements in Q2 2025, highlighted by positive Phase 2b CORAL trial results for Haduvio™ in treating chronic cough in IPF patients. The trial demonstrated statistically significant reductions in 24-hour cough frequency across all dose groups, with the highest dose (108mg BID) achieving a 60.2% reduction from baseline (p<0.0001).
The company successfully completed a $115 million underwritten offering in June 2025, ending Q2 with $203.9 million in cash and equivalents, extending runway into 2029. Q2 financial results showed R&D expenses of $9.4 million (down from $10.0 million in Q2 2024) and a net loss of $12.3 million. The company plans to request an End-of-Phase 2 FDA meeting in Q4 2025 and aims to initiate Phase 3 trials in H1 2026.
Trevi Therapeutics (Nasdaq: TRVI), a clinical-stage biopharmaceutical company, will host a conference call and webcast on August 7, 2025, at 4:30 p.m. ET to discuss Q2 2025 financial results and provide a corporate update. The company is developing Haduvio™ (oral nalbuphine ER) for treating chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease, and refractory chronic cough.
Investors can join via phone at (877) 870 4263 (domestic) or (412) 317 0790 (international). A webcast will be available in the 'Investors & News' section of TreviTherapeutics.com, with a 30-day replay option.
Trevi Therapeutics (NASDAQ:TRVI), a clinical-stage biopharmaceutical company, has announced its participation in two upcoming biotech conferences in August 2025. The company, which is developing Haduvio™ (oral nalbuphine ER) for chronic cough conditions, will be represented at Oppenheimer's 2025 Biotech in the Berkshires (August 4-6) and Stifel's 2025 Biotech Summer Summit (August 11-13).
President and CEO Jennifer Good will attend both events, with Chief Commercial Officer Farrell Simon joining for a fireside chat at the Stifel conference on August 11 at 1:00 p.m. ET.
Trevi Therapeutics (NASDAQ:TRVI), a clinical-stage biopharmaceutical company, announced its participation in the upcoming Leerink Partners Therapeutics Forum focused on I&I and Metabolism. The event will be held from July 8-9 in Boston, Massachusetts. The company's senior management, including President and CEO Jennifer Good and CFO Lisa Delfini, will be in attendance.
Trevi is currently developing Haduvio™ (oral nalbuphine ER), an investigational therapy for chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC).